MARKET WIREYahoo Finance UK • 17h ago
Vor Biopharma Inc. (VOR) stock price, news, quote and historyYahoo Finance UK report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
Why VOR Stock dropped -5.88% Today — RQD Quant Desk Flash
$19.68 -5.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $19.43
Vor Biopharma Inc. (VOR) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $1.16B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on VOR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is VOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Vor Biopharma Inc. (NASDAQ: VOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $19.68 (-5.88% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VOR ranks #421 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does VOR compare to IMTX and INBX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VOR carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.08B) and INBX (Inhibrx Biosciences Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.06B). Among the 5-stock peer group, VOR leads on earnings multiple (N/A) while VOR leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for VOR?
▼
Per VOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817229), Vor Biopharma Inc. generated $0 in revenue, -$696.0M in net income, and -$143.7M in free cash flow against $464.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $19.43 (-1.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VOR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY VOR SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)
FRED Regime × Technicals: 68% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$19.06-0.2% Next Q
34
Q2 (-2Q)Grade E$19.03+2.7% Next Q
37
Q3 (-1Q)Grade E$19.54+0.7% Next Q
39
CurrentGrade D-$19.68-7% Hist 90D α
42
Trajectory: E (34) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VOR Turnaround Squeeze
While VOR currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.64) and Max Pain ($20.66) forces dealer call-delta covering toward $27.30.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VOR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VOR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VOR Stock dropped -5.88% Today — RQD Quant Desk Flash
Vor Biopharma Inc. (VOR) dropped -5.88% to $19.68, trading at 68% of its 52-week range ($6.5 – $26). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 68% of its 52-week range ($6.5 – $26) with RSI-14 at 50 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $19.68 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VOR Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 20h ago
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 23h ago
Vor Biopharma Stock Gets A Lift From Kidney Disease Trial ResultsSimply Wall St report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
Stock sales could carry up to 3% commissions under Vor Biopharma (VOR)'s new sales agreement.Stock Titan report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Stifel reiterates Vor Biopharma stock rating on trial milestone By Investing.comInvesting.com UK report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Vor Biopharma (VOR) Short Interest & Short Float | Updated Oct 2026 $VORMarketBeat report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.siam.in/ • 1d ago
Vor (VOR) Sinks -6.77% as Volume Spikes on Downside 2026-10-18 - Bollinger Squeezehttps://www.siam.in/ report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw FocusYahoo Finance report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateCompleted enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 regi
MARKET WIREBenzinga • 3d ago
Vor Biopharma Files Prospectus For Offering $150M Common Shareshttps://www.sec.gov/Archives/edgar/data/1817229/000119312526439975/d180165d424b5.htm
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VOR)
- ✓Walkthrough of VOR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VOR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +33.79%▲ ASCENDING CHANNEL
2026-11-03O $20.91H $20.91L $19.68C $19.68VOL 759.6K
RES: $29.29SUP: $17.79SMA50: $20.64SMA200: $17.39
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VOR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VOR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VOR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VOR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VOR)
Health Care Rank #421 of 1016
⚔️ IMTX vs VOR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VOR vs. IMTX, INBX, TSHA, LYCA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vor Biopharma Inc. (VOR) ranks #421 by composite RQD confidence (42/100, grade D-) and #337 by equity capitalization ($1.16B). Within this direct 5-issuer industry benchmark cohort, VOR leads on earnings valuation at N/A trailing P/E, while VOR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with VOR at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VOR
ACTIVE
Vor Biopharma Inc. | D- | 42/100 | — | — | -35.0% | -5.88% | $1.16B | Benchmark Subject |
| IMTX Immatics N.V. | D | 44/100 | — | — | — | -1.50% | $1.08B | /imtx-vs-vor → |
| INBX Inhibrx Biosciences Inc. | E | 18/100 | — | — | -35.0% | -2.54% | $1.06B | /inbx-vs-vor → |
| TSHA Taysha Gene Therapies Inc. | E | 31/100 | — | — | -35.0% | -2.13% | $1.35B | /tsha-vs-vor → |
| LYCA Lycia Therapeutics Inc. | D+ | 54/100 | — | — | — | -4.80% | $1.38B | /lyca-vs-vor → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817229In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vor Biopharma Inc. (VOR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$696.0M, operating cash flow of -$142.7M, and free cash flow of -$143.7M (-43.8% YoY). On the balance sheet, VOR closed FY2025 with $464.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$696.0M | -$142.7M | -$143.7M | $464.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$116.9M | -$99.7M | -$99.9M | $142.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$117.9M | -$100.3M | -$100.3M | — | — |
3. VOR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VOR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Vor Biopharma Inc. (NASDAQ: VOR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $19.68 (-5.88% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VOR ranks #421 in composite RQD confidence.
How does VOR compare to IMTX and INBX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VOR carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMTX (Immatics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.08B) and INBX (Inhibrx Biosciences Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.06B). Among the 5-stock peer group, VOR leads on earnings multiple (N/A) while VOR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VOR?
Per VOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817229), Vor Biopharma Inc. generated $0 in revenue, -$696.0M in net income, and -$143.7M in free cash flow against $464.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VOR trading relative to its 50-day, 200-day, and 52-week technical levels?
VOR last traded at $19.68 (-5.88% on volume of 759,603 shares), positioning the stock -4.65% below its 50-day simple moving average ($20.64) and +13.17% above its 200-day simple moving average ($17.39). Across its 52-week range of $6.50 to $26.00, VOR sits at the 67.6% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.22 to $22.14).
VOR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VOR stock moving today?
Why VOR Stock dropped -5.88% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 42/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
VOR — Vor Biopharma Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:08Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, VOR scores 46 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
- Fundamental Cash Engine: 8 / 20. Per the RQD rating, ROIC is -35% and FCF yield is -11.61%. For a prospective investor, this indicates the business is not currently generating cash returns on invested capital, so valuation rests on future outcomes rather than present earnings power.
- Whale 13F Flow: 14 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The moderate score suggests some institutional interest, but the underlying holder data in this dossier is not itemized (see Analyst View section).
- Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The lowest pillar score signals weak insider-conviction signals in the source data.
- Macro Regime Fit: 11 / 20. Per the RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market, offering no defensive dampening.
- Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings place the balance sheet in a weak forensic posture, with a low Piotroski score pointing to limited financial-quality strength.
Taken together, the rating frames VOR as a high-risk, cash-consuming biotechnology name with weak insider signals and a weak forensic profile. Upside scenarios depend on pipeline or regulatory outcomes not captured in these scores, while the valuation tradeoff is that negative ROIC and FCF yield leave little current cash support for the share price.
Business
Vor Biopharma Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. Per the profile, the company has a market capitalization of $1.2B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each listed period per the SEC financials, so the source data does not show a revenue-generating business.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-371.6M | $-696.0M | N/A | $-143.7M | $396.5M | N/A |
| FY 2024 | $0.0M | $-121.2M | $-116.9M | N/A | $-99.9M | $81.9M | N/A |
| FY 2023 | $0.0M | $-126.0M | $-117.9M | N/A | $-100.3M | N/A | N/A |
Per the SEC financials, the company reports operating losses in every listed period, with FY 2025 operating loss of $-371.6M and net loss of $-696.0M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the SEC financials, cash rose to $396.5M in FY 2025 from $81.9M in FY 2024, while Debt/Equity is 0.5 per the RQD rating.
Recent Catalysts & News Wire Analysis
Per the news wire, six items are listed, all tagged to VOR:
- Yahoo Finance UK and Yahoo! Finance Canada general market-report items (YELLOW, MARKET WIRE).
- Simply Wall St item titled "Vor Biopharma Stock Gets A Lift From Kidney Disease Trial Results" (YELLOW, MARKET WIRE).
- Stock Titan item on a new sales agreement with commissions of up to 3% (RED, RISK WATCH).
- Investing.com UK item on a Stifel rating reiteration tied to a trial milestone (YELLOW, MARKET WIRE).
- MarketBeat short interest item, updated Oct 2026 (YELLOW, MARKET WIRE).
The only item flagged RISK WATCH is the at-the-market sales agreement, which implies potential equity dilution as a risk. The butterfly supply-chain graph contains no proprietary signals.
Open Questions
- What are the company's products, pipeline stage, and revenue model, given zero reported revenue?
- What are the terms and dilution implications of the at-the-market sales agreement cited in the news wire?
- What is the cash runway implied by $396.5M in cash against FY 2025 FCF of $-143.7M?
- Which institutional holders and insiders are driving the 13F and Form 4 readings behind the RQD pillar scores?
- What drove the kidney disease trial result and Stifel rating reiteration referenced in news items?
VOR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Vor Biopharma Inc. (VOR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 17h ago
Vor Biopharma Inc. (VOR) stock price, news, quote and history Yahoo Finance UK report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 20h ago
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 23h ago
Vor Biopharma Stock Gets A Lift From Kidney Disease Trial Results Simply Wall St report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
Stock sales could carry up to 3% commissions under Vor Biopharma (VOR)'s new sales agreement. Stock Titan report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Stifel reiterates Vor Biopharma stock rating on trial milestone By Investing.com Investing.com UK report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Vor Biopharma (VOR) Short Interest & Short Float | Updated Oct 2026 $VOR MarketBeat report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.siam.in/ • 1d ago
Vor (VOR) Sinks -6.77% as Volume Spikes on Downside 2026-10-18 - Bollinger Squeeze https://www.siam.in/ report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus Yahoo Finance report covering Vor Biopharma Inc. (VOR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
VOR Bull vs. Bear Conversation Board — What's Your Call at $19.68?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VOR 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $22.58 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is VOR (D • RQD 46/100) a Buy at $20.91?
Welcome to the VOR (Vor Biopharma Inc.) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $16.94 (-19.0%)
Spot @ $20.91 Pump the brakes on VOR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on VOR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Vor Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $25.51 (+22.0%)
Spot @ $20.91 VOR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on VOR, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $20.91 (52-wk range $6.50 - $26.76), any beat on forward guidance forces shorts and underweight funds to chase.